ReviewBrain and behavior2026
Research Progress of Ferroptosis in Cerebral Infarction.
Review in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comorbid mechanisms of neuroinflammation and astrocytic ferroptosis in neurological disorders: A vicious cycle (Review).Biomedical reports · 2026Review
- Impact of Oxidative Stress-Driven Ferroptosis in Neurodegeneration.International journal of molecular sciences · 2026Review
- Research Progress of Ferroptosis in Cerebral Infarction.Brain and behavior · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo synthesize current mechanistic insights and translational progress on ferroptosis, a regulated, iron-dependent, nonapoptotic cell death pathway in the pathophysiology and treatment of cerebral infarction (ischemic stroke), and to outline therapeutic opportunities and remaining gaps for clinical application.
methodNarrative, focused review of preclinical and translational studies (in vitro, ex vivo, and in vivo ischemia/reperfusion and middle cerebral artery occlusion models), alongside emerging biomarker, nanocarrier, and gene/RNA-based strategies reported up to 2025. Evidence was organized across five domains: (1) redox and lipid peroxidation biology; (2) iron metabolism and ferritinophagy; (3) mitochondrial dysfunction; (4) neuroinflammation and blood-brain barrier integrity; and (5) therapeutic development and early clinical exploration. FINDING: Ferroptosis in cerebral infarction is driven by glutathione depletion, glutathione peroxidase-4 (GPX4) inactivation, and iron-catalyzed lipid peroxidation of polyunsaturated phospholipids, with acyl-CoA synthetase long-chain family member-4 (ACSL4) and lysophosphatidylcholine acyltransferase-3 (LPCAT3) priming membranes for oxidative injury. Mitochondrial reactive oxygen species, iron-sulfur cluster instability, and cardiolipin oxidation amplify ferroptotic signaling, while ferroptosis-inflammation crosstalk (via damage-associated molecular patterns and microglial activation) aggravates secondary injury and blood-brain barrier disruption. Candidate biomarkers (e.g., oxylipins, 8-iso-prostaglandin F2α, GPX4 fragments; gene pairs such as CDKN1A/JUN; NFE2L2 pathway readouts) show promise for patient stratification. Pharmacological approaches-including radical-trapping antioxidants (ferrostatin-1, liproxstatin-1), iron chelation, and nuclear factor erythroid 2-related factor 2 (Nrf2) activation-consistently reduce infarct volume and improve function in animal models. Nanoparticle formulations enhance brain delivery of ferroptosis modulators, and RNA/gene-targeted strategies (e.g., SLC7A11/GPX4/FSP1 axes; exosomal noncoding RNAs) expand the therapeutic toolkit. Clinically, iron-modulating strategies in ischemic stroke suggest feasibility; however, dedicated, biomarker-guided ferroptosis trials remain limited.
conclusionFerroptosis represents a convergent, actionable mechanism of ischemic neuronal death and secondary brain injury. Multimodal interventions that combine lipid peroxidation control, iron homeostasis, mitochondrial protection, and inflammation resolution are biologically compelling. Key next steps include: validating real-time biomarkers for patient selection and timing; optimizing brain-penetrant delivery systems; integrating ferroptosis modulation with reperfusion therapies; and advancing rigorously designed phase II/III trials to establish efficacy and safety in defined stroke subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.